Emergent Biosolutions (NYSE:EBS) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Emergent Biosolutions (NYSE:EBS) from a buy rating to a hold rating in a research report released on Sunday morning.

A number of other equities analysts have also commented on EBS. Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a report on Tuesday, December 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Stock Performance

NYSE:EBS opened at $8.29 on Friday. The stock has a market capitalization of $435.39 million, a P/E ratio of 9.87 and a beta of 2.41. The company has a current ratio of 5.01, a quick ratio of 2.41 and a debt-to-equity ratio of 1.09. Emergent Biosolutions has a 1 year low of $4.02 and a 1 year high of $14.06. The firm has a 50 day moving average of $11.29 and a 200-day moving average of $10.41.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54). Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%.The business had revenue of $148.70 million for the quarter, compared to the consensus estimate of $217.50 million. As a group, sell-side analysts anticipate that Emergent Biosolutions will post -0.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in Emergent Biosolutions in the 2nd quarter valued at $31,000. Ameritas Investment Partners Inc. bought a new stake in shares of Emergent Biosolutions during the second quarter worth $35,000. Torren Management LLC acquired a new position in shares of Emergent Biosolutions during the fourth quarter valued at $37,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Emergent Biosolutions during the fourth quarter valued at $45,000. Finally, Raymond James Financial Inc. bought a new position in Emergent Biosolutions in the second quarter valued at about $53,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.